Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00703-5233-93 00703-5233 Daunorubicin Hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous April 1, 2004 June 30, 2016 In Use
61958-0301-01 61958-0301 Daunorubicin DaunoXome Chemotherapy Antitumor Antibiotic Anthracycline Intravenous April 8, 1996 July 1, 2011 No Longer Used
10885-0001-01 10885-0001 Daunorubicin DaunoXome Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 13, 2012 April 16, 2016 No Longer Used
00003-0524-11 00003-0524 Dasatinib Sprycel 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 27, 2006 In Use
00003-0527-11 00003-0527 Dasatinib Sprycel 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 27, 2006 In Use
00003-0528-11 00003-0528 Dasatinib Sprycel 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 27, 2006 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct. 28, 2010 In Use
00003-0857-22 00003-0857 Dasatinib Sprycel 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct. 28, 2010 In Use
54868-5759-00 54868-5759 Dasatinib Sprycel 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 12, 2007 In Use
60505-3628-06 60505-3628 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3629-06 60505-3629 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3630-06 60505-3630 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3631-03 60505-3631 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3816-03 60505-3816 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3817-03 60505-3817 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0233-60 66993-0233 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0234-60 66993-0234 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0235-60 66993-0235 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0236-30 66993-0236 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0237-30 66993-0237 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0238-30 66993-0238 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
00003-0852-11 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 3, 2009 Jan. 26, 2011 In Use
00003-0852-22 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2008 In Use
50419-0395-01 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 31, 2019 In Use
50419-0395-72 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral March 3, 2021 In Use
54868-5428-00 54868-5428 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 13, 2006 June 30, 2013 No Longer Used
54868-5429-00 54868-5429 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent March 20, 2008 June 30, 2013 No Longer Used
54868-5867-00 54868-5867 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent March 20, 2008 June 30, 2013 No Longer Used
55513-0006-01 55513-0006 Darbepoetin alfa Aranesp 200.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0010-01 55513-0010 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 March 31, 2009 No Longer Used
55513-0010-04 55513-0010 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 March 31, 2009 No Longer Used
55513-0011-01 55513-0011 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 Nov. 30, 2008 No Longer Used
55513-0011-04 55513-0011 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 Nov. 30, 2008 No Longer Used
55513-0012-01 55513-0012 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 Dec. 31, 2008 No Longer Used
55513-0012-04 55513-0012 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 Dec. 31, 2008 No Longer Used
55513-0013-01 55513-0013 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 April 30, 2009 No Longer Used
55513-0013-04 55513-0013 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct. 1, 2001 April 30, 2009 No Longer Used
55513-0028-01 55513-0028 Darbepoetin alfa Aranesp 200.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 14, 2006 In Use
55513-0032-01 55513-0032 Darbepoetin alfa Aranesp 500.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 7, 2006 In Use
55513-0037-01 55513-0037 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb. 18, 2011 Nov. 30, 2008 No Longer Used
55513-0037-04 55513-0037 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb. 18, 2011 Nov. 30, 2008 No Longer Used
55513-0048-01 55513-0048 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb. 10, 2004 Feb. 28, 2009 No Longer Used
55513-0053-01 55513-0053 Darbepoetin alfa Aranesp 150.0 ug/.75mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0053-04 55513-0053 Darbepoetin alfa Aranesp 150.0 ug/.75mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use

Found 10,000 results in 15 millisecondsExport these results